Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $502.07 million. The enterprise value is $264.30 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, before market open.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 130.07 million shares outstanding. The number of shares has increased by 24.08% in one year.
| Current Share Class | 130.07M |
| Shares Outstanding | 130.07M |
| Shares Change (YoY) | +24.08% |
| Shares Change (QoQ) | +12.52% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 42.43% |
| Float | 129.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12,245.61 |
| Forward PS | n/a |
| PB Ratio | 1.90 |
| P/TBV Ratio | 2.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6,446.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.55, with a Debt / Equity ratio of 0.16.
| Current Ratio | 18.55 |
| Quick Ratio | 18.35 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -57.76 |
Financial Efficiency
Return on equity (ROE) is -50.57% and return on invested capital (ROIC) is -30.62%.
| Return on Equity (ROE) | -50.57% |
| Return on Assets (ROA) | -28.17% |
| Return on Invested Capital (ROIC) | -30.62% |
| Return on Capital Employed (ROCE) | -35.67% |
| Weighted Average Cost of Capital (WACC) | 5.08% |
| Revenue Per Employee | $695 |
| Profits Per Employee | -$1.49M |
| Employee Count | 57 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -681,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.70% in the last 52 weeks. The beta is 0.17, so Altimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -30.70% |
| 50-Day Moving Average | 4.47 |
| 200-Day Moving Average | 4.45 |
| Relative Strength Index (RSI) | 38.59 |
| Average Volume (20 Days) | 3,234,837 |
Short Selling Information
The latest short interest is 25.13 million, so 19.32% of the outstanding shares have been sold short.
| Short Interest | 25.13M |
| Short Previous Month | 24.16M |
| Short % of Shares Out | 19.32% |
| Short % of Float | 19.45% |
| Short Ratio (days to cover) | 5.02 |
Income Statement
In the last 12 months, Altimmune had revenue of $41,000 and -$88.09 million in losses. Loss per share was -$1.00.
| Revenue | 41,000 |
| Gross Profit | -66.39M |
| Operating Income | -94.49M |
| Pretax Income | -88.77M |
| Net Income | -88.09M |
| EBITDA | -94.38M |
| EBIT | -94.49M |
| Loss Per Share | -$1.00 |
Full Income StatementBalance Sheet
The company has $273.46 million in cash and $35.69 million in debt, with a net cash position of $237.77 million or $1.83 per share.
| Cash & Cash Equivalents | 273.46M |
| Total Debt | 35.69M |
| Net Cash | 237.77M |
| Net Cash Per Share | $1.83 |
| Equity (Book Value) | 224.89M |
| Book Value Per Share | 2.03 |
| Working Capital | 263.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$67.54 million and capital expenditures -$11,000, giving a free cash flow of -$67.55 million.
| Operating Cash Flow | -67.54M |
| Capital Expenditures | -11,000 |
| Free Cash Flow | -67.55M |
| FCF Per Share | -$0.52 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -230,460.98% |
| Pretax Margin | -216,521.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.08% |
| Shareholder Yield | -24.08% |
| Earnings Yield | -17.55% |
| FCF Yield | -13.45% |
Analyst Forecast
The average price target for Altimmune is $15.50, which is 301.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | 301.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 607.09% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Altimmune has an Altman Z-Score of 1.26 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.26 |
| Piotroski F-Score | 3 |
